<?xml version="1.0" encoding="UTF-8" standalone="no" ?>
<rss version="2.0">
  <channel>
    <title>Bos, P.K.</title>
    <link>http://repub.eur.nl/res/aut/17168/</link>
    <description>List of Publications</description>
    <language>en</language>
    <image>
      <url>http://repub.eur.nl/static-eur/img/logo.png</url>
      <title>RePub, Erasmus University Rotterdam</title>
      <link>http://repub.eur.nl</link>
    </image>
    <item>
      <title>Does infrapatellar fat pad resection in total knee arthroplasty impair clinical outcome? A systematic review (Article)</title>
      <link>http://repub.eur.nl/res/pub/39823/</link>
      <pubDate>2013-04-08T00:00:00Z</pubDate>
      <description>Introduction: The infrapatellar fat pad (IPFP) is often removed during total knee arthroplasty (TKA). No evidence based guidelines on changes in clinical outcome have yet been described. The aim of this review is to investigate whether regular removal of the IPFP during TKA should be performed. Material and methods: Seven databases were systematically searched. Clinical studies, in which TKA with IPFP resection was compared with IPFP preservation, were included. Risk of bias was assessed using the Cochrane collaboration tool. Studies reporting anterior knee pain, patellar tendon length, range of motion, patellar vascularisation or functional outcome were included. Results: The indication for TKA varied in the different studies: osteoarthritis (OA), rheumatic arthritis (RA) and multiple indications (OA, RA and osteonecrosis). After IPFP resection: 1. For OA, no differences in function, range of motion, and anterior knee pain were found. 2. In the RA study, there was a trend towards more discomfort and a decrease in function. 3. In OA and RA patients a decrease in patellar tendon length was observed. 4. One study reported no decrease in patellar vascularisation. Discussion: Limitations of this review are the high risk of bias scores of the included studies, the varying outcome measures, follow up, number and type of participants. Randomised clinical trials are required to support or refute the results, contributing to a possible future evidence based guideline on IPFP resection during TKA. </description>
    </item> <item>
      <title>Effect of arthritic synovial fluids on the expression of immunomodulatory factors by mesenchymal stem cells: An explorative in vitro study (Article)</title>
      <link>http://repub.eur.nl/res/pub/39299/</link>
      <pubDate>2012-12-01T00:00:00Z</pubDate>
      <description>Background:In diseased joints, the catabolic environment results in progressive joint damage. Mesenchymal stem cells (MSCs) can have immunomodulatory effects by secreting anti-inflammatory factors. To exert these effects, MSCs need to be triggered by proinflammatory cytokines. To explore the potential of MSCs as a treatment for diseased joints, we studied the effect of synovial fluid (SF) from donors with different joint diseases and donors without joint pathology on the immunomodulatory capacities of human MSCs in vitro. We hypothesized that SF of diseased joints influences the immunomodulatory effects of MSCs. Materials and Methods: MSCs were cultured in medium with SF of six osteoarthritis (OA) or six rheumatoid arthritis (RA) donors and three donors without joint pathology were used as control. Gene expressions of IL-6, HGF, TNFa, TGFb1, and indoleamine 2,3-dioxygenase (IDO) were analyzed. L-kynurenine concentration in conditioned medium (CM) by MSCs with SF was determined as a measure of IDO activity by MSCs. Furthermore, the effect of CM with SF on proliferation of activated lymphocytes was analyzed. Results: Addition of SF significantly up-regulated the mRNA expression of IL-6 and IDO in MSCs. SF(OA) induced significantly higher expression of IDO than SF(control), although no difference in IDO activity of the MSCs could be shown with a L-kynurenine assay. Medium conditioned by MSCs with SF(OA or RA) suppressed activated lymphocyte proliferation in vitro more than medium conditioned by MSCs without SF or with SF(control). Discussion: SF can influence the expression of genes involved in immunomodulation by MSCs and the effect on lymphocyte proliferation. We found indications for disease-specific differences between SFs but the variation between donors, even within one disease group was high. These data warrant further research to examine the potential application of MSC therapy in arthritic joints. </description>
    </item> <item>
      <title>Mesenchymal stem cells secrete factors that inhibit inflammatory processes in short-term osteoarthritic synovium and cartilage explant culture (Article)</title>
      <link>http://repub.eur.nl/res/pub/39233/</link>
      <pubDate>2012-10-01T00:00:00Z</pubDate>
      <description>Objective: Mesenchymal stem cells (MSCs) are promising candidates for osteoarthritis (OA) therapies, although their mechanism of action remains unclear. MSCs have recently been discovered to secrete anti-inflammatory cytokines and growth factors. We studied the paracrine effects of MSCs on OA cartilage and synovial explants in vitro. Design: MSC-conditioned medium was prepared by stimulating primary human MSCs with tumour necrosis factor alpha (TNFα) and (50. ng/ml each). Human synovium and cartilage explants were cultured in MSC-conditioned medium or in control medium, containing the same amount of added TNFα and IFNγ but not incubated with MSCs. Explants were analyzed for gene expression and the production of nitric oxide (NO). The presence of the inhibitor of nuclear factor kappa B alpha (IκBa) was assessed by Western blot analysis. Results: Synovial explants exposed to MSC-conditioned medium showed decreased gene expression of interleukin-1 beta (IL-1β), matrix metalloproteinase (MMP). 1 and MMP13, while suppressor of cytokine signaling (SOCS). 1 was upregulated. In cartilage, expression of IL-1 receptor antagonist (IL-1RA) was upregulated, whereas a disintegrin and metalloproteinase with thrombospondin motifs (ADAMTS). 5 and collagen type II alpha 1 (COL2A1) were downregulated. MSC-conditioned medium reduced NO production in cartilage explants and the presence of IκBa was increased in synoviocytes and chondrocytes treated with MSC-conditioned medium. Conclusions: In an inflammatory environment, MSCs secrete factors which cause multiple anti-inflammatory effects and influence matrix turnover in synovium and cartilage explants. Thereby, the presented data encourage further study of MSCs as a treatment for joint diseases. </description>
    </item> <item>
      <title>Reproducibility of 3D delayed gadolinium enhanced MRI of cartilage (dGEMRIC) of the knee at 3.0 T in patients with early stage osteoarthritis (Article)</title>
      <link>http://repub.eur.nl/res/pub/39343/</link>
      <pubDate>2012-08-13T00:00:00Z</pubDate>
      <description>Objectives: To assess the reproducibility of 3D delayed gadolinium-enhanced MRI of cartilage (dGEMRIC) at 3 T in early stage knee osteoarthritis (OA) patients. Methods: In 20 patients, 3D dGEMRIC at 3 T was acquired twice within 7 days. To correct for patient motion during acquisition, all images were rigidly registered in 3D. Eight anatomical cartilage ROIs were analysed on both images of each patient. Capability of dGEMRIC to yield T1 maps that reproducibly distinguish spatial differences in cartilage quality was assessed in two ROIs within a single slice in each patient. Reproducibility was assessed using ICCs and Bland-Altman plots. Results: ICCs ranged from 0.87 to 0.95, indicating good reproducibility. T1 maps revealed reproducible spatial differences in cartilage quality (ICC 0.79). Based on the Bland-Altman plots, we defined a threshold of 95 ms to determine if a change in dGEMRIC outcome in longitudinal research was statistically significant. Conclusions: 3D knee dGEMRIC at 3 T combined with 3D image registration is a highly reproducible measure of cartilage quality in early stage OA. Therefore, dGEMRIC may be a valuable tool in the non-invasive evaluation of cartilage quality changes in longitudinal research in patients with early stage OA and focal cartilage defects. Key Points: • Delayed gadolinium-enhanced magnetic resonance imaging of cartilage (dGEMRIC) can assess osteoarthritis • dGEMRIC yields highly reproducible T1 values in early stage osteoarthritic patients • A threshold was established to determine significant changes in dGEMRIC outcomes • dGEMRIC can be used to evaluate cartilage quality in longitudinal research </description>
    </item> <item>
      <title>Survival of short hip stems with a "modern", trochanter-sparing design - a systematic literature review (Article)</title>
      <link>http://repub.eur.nl/res/pub/39314/</link>
      <pubDate>2012-07-01T00:00:00Z</pubDate>
      <description>Modern total hip arthroplasty delivers excellent and reproducible results. New implant developments include a wide range of implants with a bone and tissue sparing design, including short femoral stems. This review was performed to provide an overview on the currently published survival results of short stems to allow comparison with the results of traditional hip stems. A literature search was performed to identify publications on short stems with a "modern" trochanter sparing design including implant survival information. Information was collected on the study population, follow-up time, implants used, implant survival and functional scores. The revision rate per 100 observed component years was calculated and compared to data presented in national arthroplasty registries. The methodological quality was assessed by employing a score specific to survival assessment of hip stems. In the course of 16 individual searches in EMBASE and Medline, 460 potentially eligible articles were identified. After thorough screening, 14 articles were deemed applicable. The variability in quality of the publications was high. No association between survival outcome and publication quality was apparent. The total revision rate over all studies was found to be 0.38 per 100 component years with endpoint "stem revision for any reason". The survival rate of these stems is encouraging and appears to be comparable with that of more traditional uncemented stems. However, only few mid-term and long-term studies are available. Reports with longer follow-up are needed to draw further conclusions. </description>
    </item> <item>
      <title>Phenotypic spectrum of the SMAD3-related aneurysms-osteoarthritis syndrome (Article)</title>
      <link>http://repub.eur.nl/res/pub/35039/</link>
      <pubDate>2012-01-01T00:00:00Z</pubDate>
      <description>Background: Aneurysmseosteoarthritis syndrome (AOS) is a new autosomal dominant syndromic form of thoracic aortic aneurysms and dissections characterised by the presence of arterial aneurysms and tortuosity, mild craniofacial, skeletal and cutaneous anomalies, and early-onset osteoarthritis. AOS is caused by mutations in the SMAD3 gene. Methods: A cohort of 393 patients with aneurysms without mutation in FBN1, TGFBR1 and TGFBR2 was screened for mutations in SMAD3. The patients originated from The Netherlands, Belgium, Switzerland and USA. The clinical phenotype in a total of 45 patients from eight different AOS families with eight different SMAD3 mutations is described. In all patients with a SMAD3 mutation, clinical records were reviewed and extensive genetic, cardiovascular and orthopaedic examinations were performed. Results Five novel SMAD3 mutations (one nonsense, two missense and two frame-shift mutations) were identified in five new AOS families. A follow-up description of the three families with a SMAD3 mutation previously described by the authors was included. In the majority of patients, early-onset joint abnormalities, including osteoarthritis and osteochondritis dissecans, were the initial symptom for which medical advice was sought. Cardiovascular abnormalities were present in almost 90% of patients, and involved mainly aortic aneurysms and dissections. Aneurysms and tortuosity were found in the aorta and other arteries throughout the body, including intracranial arteries. Of the patients who first presented with joint abnormalities, 20% died suddenly from aortic dissection. The presence of mild craniofacial abnormalities including hypertelorism and abnormal uvula may aid the recognition of this syndrome. Conclusion: The authors provide further insight into the phenotype of AOS with SMAD3 mutations, and present recommendations for a clinical work-up.</description>
    </item> <item>
      <title>Effectiveness of intramuscular corticosteroid injection versus placebo injection in patients with hip osteoarthritis: Design of a randomized double-blinded controlled trial (Article)</title>
      <link>http://repub.eur.nl/res/pub/34330/</link>
      <pubDate>2011-12-13T00:00:00Z</pubDate>
      <description>Background: Recent international guidelines recommend intra-articular corticosteroid injections for patients with hip osteoarthritis who have moderate to severe pain and do not respond satisfactorily to oral analgesic/anti- inflammatory agents. Of the five available randomized controlled trials, four showed positive effects with respect to pain reduction. However, intra-articular injection in the hip is complex because the joint is adjacent to important neurovascular structures and cannot be palpated. Therefore fluoroscopic or ultrasound guidance is needed. The systemic effect of corticosteroids has been studied in patients with impingement shoulder pain. Gluteal corticosteroid injection was almost as effective as ultrasound-guided subacromial corticosteroid injection. Such a clinically relevant effect of a systemic corticosteroid injection offers a less complex alternative for treatment of patients with hip osteoarthritis not responsive to oral pain medication. Methods/Design. This is a double-blinded, randomized controlled trial. A total of 135 patients (aged &gt; 40 years) with hip osteoarthritis and persistent pain despite oral analgesics visiting a general practitioner or orthopaedic surgeon will be included. They will be randomized to a gluteal intramuscular corticosteroid injection or a gluteal intramuscular placebo (saline) injection. The randomization will be stratified for setting (general practitioner and outpatient clinics of department of orthopaedics). Treatment effect will be evaluated by questionnaires at 2, 4, 6, and 12 weeks follow-up and a physical examination at 12 weeks. Primary outcome is severity of hip pain reported by the patients at 2-week follow-up. Statistical analyses will be based on the intention-to-treat principle. Discussion. This study will evaluate the effectiveness of an intramuscular corticosteroid injection on pain in patients with hip osteoarthritis. Patient recruitment has started. Trial Registration. This trial is registered in the Dutch Trial Registry: number NTR2966. </description>
    </item> <item>
      <title>Platelet-rich plasma releasate inhibits inflammatory processes in osteoarthritic chondrocytes (Article)</title>
      <link>http://repub.eur.nl/res/pub/33820/</link>
      <pubDate>2011-11-01T00:00:00Z</pubDate>
      <description>Background: Platelet-rich plasma (PRP) has recently been postulated as a treatment for osteoarthritis (OA). Although anabolic effects of PRP on chondrocytes are well documented, no reports are known addressing effects on cartilage degeneration. Since OA is characterized by a catabolic and inflammatory joint environment, the authors investigated whether PRP was able to counteract the effects of such an environment on human osteoarthritic chondrocytes.Hypothesis: Platelet-rich plasma inhibits inflammatory effects of interleukin-1 (IL-1) beta on human osteoarthritic chondrocytes.Study Design: Controlled laboratory study.Methods: Human osteoarthritic chondrocytes were cultured in the presence of IL-1 beta to mimic an osteoarthritic environment. Medium was supplemented with 0%, 1%, or 10% PRP releasate (PRPr, the active releasate of PRP). After 48 hours, gene expression of collagen type II alpha 1 (COL2A1), aggrecan (ACAN), a disintegrin and metalloproteinase with thrombospondin motifs (ADAMTS)4, ADAMTS5, matrix metalloproteinase (MMP)13, and prostaglandin-endoperoxide synthase (PTGS)2 was analyzed. Additionally, glycosaminoglycan (GAG) content, nitric oxide (NO) production, and nuclear factor kappa B (NFB) activation were studied.Results: Platelet-rich plasma releasate diminished IL-1 beta-induced inhibition of COL2A1 and ACAN gene expression. The PRPr also reduced IL-1 beta-induced increase of ADAMTS4 and PTGS2 gene expression. ADAMTS5 gene expression and GAG content were not influenced by IL-1 beta or additional PRPr. Matrix metalloproteinase 13 gene expression and NO production were upregulated by IL-1 beta but not affected by added PRPr. Finally, PRPr reduced IL-1 beta-induced NFB activation to control levels containing no IL-1 beta.Conclusion: Platelet-rich plasma releasate diminished multiple inflammatory IL-1 beta-mediated effects on human osteoarthritic chondrocytes, including inhibition of NFB activation.Clinical Relevance: Platelet-rich plasma releasate counteracts effects of an inflammatory environment on genes regulating matrix degradation and formation in human chondrocytes. Platelet-rich plasma releasate decreases NFB activation, a major pathway involved in the pathogenesis of OA. These results encourage further study of PRP as a treatment for OA. </description>
    </item> <item>
      <title>Risk factors of recurrent hamstring injuries: A systematic review (Article)</title>
      <link>http://repub.eur.nl/res/pub/39358/</link>
      <pubDate>2011-10-19T00:00:00Z</pubDate>
      <description>Background: Although recurrent hamstring injury is a frequent problem with a significant impact on athletes, data on factors determining the risk for a recurrent hamstring injury are scarce. Objective: To systematically review the literature and provide an overview of risk factors for re-injury of acute hamstring muscle injuries. Study design: Prospective studies on risk factors for re-injury following acute hamstring injuries were systematically reviewed. Medical databases and reference lists of the included articles were searched. Two reviewers independently selected potential studies and assessed methodological quality; one reviewer extracted the data. A best-evidence synthesis of all studied risk factors was performed. Results: Of the 131 articles identified, five prospective follow-up studies fulfilled our inclusion criteria. These studies reported a recurrence incidence of 13.9-63.3% in the same playing season up to 2 years after initial injury. Limited evidence for three risk factors and one protective factor for recurrent hamstring injury was found; patients with a recurrent hamstring injury had an initial injury with a larger volume size as measured on MRI (47.03vs 12.42 cm3), more often had a Grade 1 initial trauma (Grade 0: 0-30.4%; Grade 1: 60.9-100%; Grade 2: 8.7%) and more often had a previous ipsilateral anterior cruciate ligament (ACL) reconstruction (66.6% vs 17.1%) independent of graft selection. Athletes in a rehabilitation programme with agility/stabilisation exercises rather than strength/stretching exercises had a lower risk for re-injury (7.7% vs 70%). No significant relationship with re-injury was found for 11 related determinants. There was conflicting evidence that a larger cross-sectional area is a risk factor for recurrent hamstring injury. Conclusions: There is limited evidence that athletes with a larger volume size of initial trauma, a Grade 1 hamstring injury and a previous ipsilateral ACL reconstruction are at increased risk for recurrent hamstring injury. Athletes seem to be at lower risk for re-injury when following agility/stabilisation exercises. Copyright Article author (or their employer) 2011.</description>
    </item> <item>
      <title>The Most Accurate Approach for Intra-Articular Needle Placement in the Knee Joint: A Systematic Review (Article)</title>
      <link>http://repub.eur.nl/res/pub/33268/</link>
      <pubDate>2011-10-01T00:00:00Z</pubDate>
      <description>Introduction: Intra-articular needle placement in the knee joint, such as injection or aspirations, are commonly used for therapeutic, diagnostic, and research purposes. Although several approaches can be used to establish an intra-articular injection or aspiration of the knee joint, the accuracy differs per approach. Objective: To summarize the evidence concerning the accuracy of different approaches for intra-articular needle placements in the knee. Additionally, to assess whether the accuracy of different approaches is related to factors such as underlying disease, severity of underlying disease, approach-related factors, and/or the rate of local reactions. Methods: The literature was systemically reviewed until July 2010. Risk of bias of the included studies was assessed by the QUADAS tool. Study characteristics were extracted; accuracy results were pooled per approach. Results: Nine studies were included. The superolateral approach with the leg in extension was studied most (230 injections) and resulted in the highest pooled accuracy of 91% (95% CI 84-99%). The lateral midpatellar approach, the anterolateral approach, and the anteromedial approach resulted in the lowest pooled accuracy rates, 85% (95% CI 68-100%), 67% (95% CI 43-91%) and 72% (95% CI 65-78%), respectively. Conclusions: The superolateral approach was investigated most and resulted in the highest pooled accuracy rate of 91% (95% CI 84-99%). Nevertheless, this approach still results in a substantial amount of extra-articular needle placements. Guidance of intra-articular needle placements by imaging techniques may enhance the accuracy. The costs and extra time associated with these techniques should be taken into consideration. </description>
    </item> <item>
      <title>Femoral Component Neck Fracture After Failed Hip Resurfacing Arthroplasty (Article)</title>
      <link>http://repub.eur.nl/res/pub/23733/</link>
      <pubDate>2011-03-11T00:00:00Z</pubDate>
      <description>Abstract: Failure on the femoral side after third-generation metal-on-metal hip resurfacing arthroplasty is suggested to be easily treated with conversion to conventional total hip arthroplasty. Clinical results of conversion for failed hip resurfacing arthroplasty with the use of primary femoral implants confirmed this for a short-term follow-up. We present a case of the occurrence of a stemmed femoral implant neck fracture in a patient who was earlier treated for a failed hip resurfacing. We advise to consider acetabular revision in case of (suspected) acetabular metal damage and to use a stem component with a relative large neck diameter.</description>
    </item> <item>
      <title>Clinically Translatable Cell Tracking and Quantification by MRI in Cartilage Repair Using Superparamagnetic Iron Oxides (Article)</title>
      <link>http://repub.eur.nl/res/pub/23698/</link>
      <pubDate>2011-03-02T00:00:00Z</pubDate>
      <description>Abstract

BACKGROUND: Articular cartilage has very limited intrinsic regenerative capacity, making cell-based therapy a tempting approach for cartilage repair. Cell tracking can be a major step towards unraveling and improving the repair process of these therapies. We studied superparamagnetic iron oxides (SPIO) for labeling human bone marrow-derived mesenchymal stem cells (hBMSCs) regarding effectivity, cell viability, long term metabolic cell activity, chondrogenic differentiation and hBMSC secretion profile. We additionally examined the capacity of synovial cells to endocytose SPIO from dead, labeled cells, together with the use of magnetic resonance imaging (MRI) for intra-articular visualization and quantification of SPIO labeled cells. METHODOLOGY/PRINICIPAL FINDINGS: Efficacy and various safety aspects of SPIO cell labeling were determined using appropriate assays. Synovial SPIO re-uptake was investigated in vitro by co-labeling cells with SPIO and green fluorescent protein (GFP). MRI experiments were performed on a clinical 3.0T MRI scanner. Two cell-based cartilage repair techniques were mimicked for evaluating MRI traceability of labeled cells: intra-articular cell injection and cell implantation in cartilage defects. Cells were applied ex vivo or in vitro in an intra-articular environment and immediately scanned. SPIO labeling was effective and did not impair any of the studied safety aspects, including hBMSC secretion profile. SPIO from dead, labeled cells could be taken up by synovial cells. Both injected and implanted SPIO-labeled cells could accurately be visualized by MRI in a clinically relevant sized joint model using clinically applied cell doses. Finally, we quantified the amount of labeled cells seeded in cartilage defects using MR-based relaxometry. CONCLUSIONS: SPIO labeling appears to be safe without influencing cell behavior. SPIO labeled cells can be visualized in an intra-articular environment and quantified when seeded in cartilage defects.</description>
    </item> <item>
      <title>Ferumoxides–protamine sulfate is more effective than ferucarbotran for cell labeling: implications for clinically applicable cell tracking using MRI (Article)</title>
      <link>http://repub.eur.nl/res/pub/17601/</link>
      <pubDate>2010-01-01T00:00:00Z</pubDate>
      <description>The use of superparamagnetic iron oxide (SPIO) for labeling cells holds great promise for clinically applicable cell tracking using magnetic resonance imaging. For clinical application, an effectively and specifically labeled cell preparation is highly desired (i.e. a large amount of intracellular iron and a negligible amount of extracellular iron). In this study we performed a direct comparison of two SPIO labeling strategies that have both been reported as efficient and clinically translatable approaches. These approaches are cell labeling using ferumoxides-protamine complexes or ferucarabotran particles. Cell labeling was performed on primary human bone marrow stromal cells (hBMSCs) and chondrocytes. For both cell types ferumoxides-protamine resulted in a higher percentage of labeled cells, a higher total iron load, a larger amount of intracellular iron and a lower amount of extracellular iron aggregates, compared with ferucarbotran. Consequently, hBMSC and chondrocyte labeling with ferumoxides-protamine is more effective and results in more specific cell labeling than ferucarbotran.</description>
    </item> <item>
      <title>Proteoglycan production is required in initial stages of new cartilage matrix formation but inhibits integrative cartilage repair (Article)</title>
      <link>http://repub.eur.nl/res/pub/16112/</link>
      <pubDate>2009-02-01T00:00:00Z</pubDate>
      <description>The optimal stimulus to repair or regenerate cartilage is not known. We therefore modulated collagen deposition, collagen crosslinking and GAG deposition simultaneously during cartilage matrix production and integrative repair, creating more insight into their role in cartilage repair processes. Insulin-like growth factor 1 (IGF-1; increases proteoglycan and collagen synthesis), beta-aminopropionitrile (BAPN; a reversible inhibitor of collagen crosslinking) and para-nitrophenyl-beta-D-xyloside (PNPX; interferes with proteoglycan production) were used. Bovine articular chondrocytes were cultured in alginate beads for 3 weeks with or without IGF-1, BAPN or PNPX alone and in all possible combinations, followed by 3 weeks in control medium. DNA content, GAG and collagen deposition and collagen crosslinks were determined. Cartilage constructs were cultured under the same conditions and histologically analysed for integration of two opposing cartilage matrices. In alginate cultures, inhibition of collagen crosslinking with BAPN, in combination with promotion of matrix synthesis using IGF1, was most beneficial for matrix deposition. Addition of PNPX was always detrimental for matrix deposition. For integration of opposing cartilage constructs, the combination of BAPN, IGF1 and temporary prevention of proteoglycan formation with PNPX was most beneficial. When a new matrix is produced, proteoglycans are important to retain collagen in the matrix. When two already formed cartilage matrices have to integrate, a temporary absence of proteoglycans and temporary inhibition of collagen crosslinking might be more beneficial in combination with stimulation of collagen production, e.g. by IGF1. Therefore, the choice of soluble factors to promote cartilage regeneration depends on the type of therapy that will be used.</description>
    </item> <item>
      <title>Cellular origin of neocartilage formed at wound edges of articular cartilage in a tissue culture experiment (Article)</title>
      <link>http://repub.eur.nl/res/pub/15171/</link>
      <pubDate>2008-02-01T00:00:00Z</pubDate>
      <description>OBJECTIVE: The regeneration capacity of cartilage in general is limited. Complete repair of partial thickness articular cartilage has only been reported in a fetal sheep model. However, in long-term culture studies of articular cartilage explants we have observed outgrowth of chondrocytes and neocartilage formation at wound edges. This illustrates that under optimal circumstances articular cartilage is capable to regenerate hyaline cartilage. Recent studies suggest the presence of mesenchymal stem cells in articular cartilage. In the present study we investigated the origin of chondrocyte outgrowth and neocartilage formation at wound edges from immature and mature articular bovine cartilage explants in vitro, in order to understand which cells are responsible for repair. DESIGN: Full-thickness explants from immature and mature animals were cultured for 4 weeks and superficial and deep zone cartilage explants of immature animals were separately cultured. RESULTS: Significant more outgrowth was observed from immature explants as compared to mature explants. At wound edges of immature explants, this outgrowth showed high cell-densities, rounded cells, the extracellular matrix contained proteoglycans and collagen types I and II. We found proliferation activity both in the superficial zone and deep zone chondrocytes in immature explants, using the Ki67 proliferation marker. In the experiment culturing immature superficial and deep zone cartilage explants separately, there was abundant new tissue formation originating from deep cartilage and almost no outgrowth from the superficial cartilage. This indicates that neocartilage originates from chondrocytes in the deep zone cartilage and not from chondrocytes in the superficial zone cartilage. CONCLUSIONS: Present data can help to understand wound healing in partial-thickness and full-thickness defects of immature and mature cartilage and can be of help in finding methods to stimulate the regeneration of articular cartilage.</description>
    </item> <item>
      <title>Cartilage Wound Healing and Integration (Doctoral Thesis)</title>
      <link>http://repub.eur.nl/res/pub/8146/</link>
      <pubDate>2006-12-06T00:00:00Z</pubDate>
      <description>The intrinsic regeneration capacity of articular cartilage following injury is limited. Partialthickness defects are not repaired and full-thickness defects are repaired with fi brocartilage. 
Untreated, these defects may progress to early osteoarthritis. The goal of surgical treatment 
of (osteo)chondral defects is to reduce symptoms, improve joint congruence by restoring the 
joint surface with the best possible tissue, and to prevent joint degeneration. Current clinical 
and experimental treatment methods, for cartilage repair and regeneration, do not result in 
durable and predictable restoration of the articular surface in damaged joints. An important 
prerequisite for durable repair of cartilage lesions is the integration of wound edges or the 
integration of repair tissue with the surrounding host cartilage. 

In the general introduction chapter (chapter 1) the morphology and molecular composition of articular cartilage is described. The incidence and natural outcome of articular cartilage defects is given as well as a short overview of current clinical and experimental surgical 
treatment techniques.</description>
    </item> <item>
      <title>Improved cartilage integration and interfacial strength after enzymatic treatment in a cartilage transplantation model (Article)</title>
      <link>http://repub.eur.nl/res/pub/8525/</link>
      <pubDate>2004-01-01T00:00:00Z</pubDate>
      <description>The objective of the present study was to investigate whether treatment of
      articular cartilage with hyaluronidase and collagenase enhances
      histological and mechanical integration of a cartilage graft into a
      defect. Discs of 3 mm diameter were taken from 8-mm diameter bovine
      cartilage explants. Both discs and annulus were either treated for 24
      hours with 0.1% hyaluronidase followed by 24 hours with 10 U/ml
      collagenase or left untreated (controls). Discs and annulus were
      reassembled and implanted subcutaneously in nude mice for 5 weeks.
      Integration of disc with surrounding cartilage was assessed histologically
      and tested biomechanically by performing a push-out test. After 5 weeks a
      significant increase in viable cell counts was seen in wound edges of the
      enzyme-treated group as compared with controls. Furthermore, matrix
      integration (expressed as a percentage of the total interface length that
      was connected; mean +/- standard error) was 83 +/- 15% in the treated
      samples versus 44 +/- 40% in the untreated controls. In the enzyme-treated
      group only, picro-Sirius Red staining revealed collagen crossing the
      interface perpendicular to the wound surface. Immunohistochemical analyses
      demonstrated that the interface tissue contained cartilage-specific
      collagen type II. Collagen type I was found only in a small region of
      fibrous tissue at the level of the superficial layer, and collagen type
      III was completely absent in both groups. A significant difference in
      interfacial strength was found using the push-out test: 1.32 +/- 0.15 MPa
      in the enzyme-treated group versus 0.84 +/- 0.14 MPa in the untreated
      controls. The study shows that enzyme treatment of cartilage wounds
      increases histological integration and improves biomechanical bonding
      strength. Enzymatic treatment may represent a promising addition to
      current techniques for articular cartilage repair.</description>
    </item> <item>
      <title>Living cells in 1 of 2 frozen femoral heads (Article)</title>
      <link>http://repub.eur.nl/res/pub/15460/</link>
      <pubDate>2003-12-01T00:00:00Z</pubDate>
      <description>Allogeneic, frozen bone is now the most commonly grafted tissue (Norman-Taylor and Villar 1997). Tissue banks collect bone material according to protocols developed with the aim of maintaining osseoinductive properties of grafts as well as preventing transmission of viral or bacterial diseases (Standards from the American Association of Tissue Banks (AATB) or from the European Association for Musculo-skeletal Transplanting (EAMST)). Standard procedures include cryopreservation of tissue at -80 degrees C, which is generally considered to devitalize the bone by killing all cells present, resulting in reduced immunogenicity of the graft. The osseoinductive properties of frozen, allogeneic bone grafts have therefore mainly been attributed to the dead bone matrix, that may provide osteoblast-stimulating growth factors and other essential proteins, and/or an osteoclast substrate to direct bone remodeling (Aspenberg et al. 1996, Kingsmill et al. 1999). Recently however, it was suggested that some cells in bone biopsies may survive standard bone bank freezing procotols. It is unclear whether vital cells are present in other bone banks and whether these cells can contribute to the clinical outcome of frozen allogeneic bone grafting. In this report, we show that frozen bone biopsies, obtained from the Erasmus Medical Center bone bank may contain living cells that can be cultured in vitro. These cultured cells were found to originate from the donor by genotyping.</description>
    </item> <item>
      <title>Specific enzymatic treatment of bovine and human articular cartilage: implications for integrative cartilage repair (Article)</title>
      <link>http://repub.eur.nl/res/pub/15549/</link>
      <pubDate>2002-04-01T00:00:00Z</pubDate>
      <description>OBJECTIVE: Chondrocyte death in articular cartilage wound edges and the subsequent lack of matrix-producing cells in the interface area are considered to be a major cause of impaired cartilage wound healing and poor integrative cartilage repair. This study was undertaken to investigate whether enzymatic matrix digestion can be used to stimulate integrative cartilage repair via a mechanism of local increase in the amount of vital chondrocytes in cartilage wound edges. METHODS: Full-thickness bovine articular cartilage samples were cultured in vitro for 14 days in standard medium. Samples were either left untreated or treated for 48 hours with 0.3% hyaluronidase or 30 units/ml highly purified collagenase VII. Nuclear and cytoplasmic changes were analyzed to determine cell viability, and the number of vital chondrocytes in wound edges was determined. Subsequently, we investigated whether increased chondrocyte density in the lesion edges resulted in better wound healing. Finally, full-thickness human tibial plateau cartilage explants were tested with similar enzyme treatment protocols to determine the clinical value of our results. RESULTS: In bovine explants a rapid onset of chondrocyte death was observed in wound edges in all treatment groups. This led to low chondrocyte density in a band of 0-150 microm from the lesion edges in untreated and hyaluronidase-treated explants. Treatment with 30 units/ml collagenase resulted in a significant increase in chondrocyte density in this area. The integration experiments demonstrated improved integration of the lesion edges after treatment with collagenase. In human articular cartilage an increase in chondrocyte density at the lesion edges could also be achieved, but only when proteoglycans were depleted from the wound edges prior to collagenase treatment. CONCLUSION: Treatment with highly purified collagenase improves integrative cartilage repair, possibly by increasing the cell density at cartilage wound edges.</description>
    </item> <item>
      <title>Growth factor expression in cartilage wound healing: temporal and spatial immunolocalization in a rabbit auricular cartilage wound model (Article)</title>
      <link>http://repub.eur.nl/res/pub/15538/</link>
      <pubDate>2001-05-01T00:00:00Z</pubDate>
      <description>OBJECTIVE: The ability of cartilage to regenerate following injury is limited, potentially leading to osteoarthritis. Integrative cartilage repair, necessary for durable restoration of cartilage lesions, can be regarded as a wound healing process. Little is known about the effects of growth factors regulating acute cartilage wound healing in vivo. In this study the temporal expression patterns of growth factors and proteoglycan content in cartilage wound edges in vivo were studied. DESIGN: Cartilage wounds were created in rabbit ear cartilage using a 6 mm biopsy punch. Specimens were subsequently harvested 1, 3, 7, 14 and 28 days after surgery. Paraffin sections were thionin stained to visualize proteoglycan loss and replacement. Immunohistochemical staining of TGFbeta1, TGFbeta3, IGF-1, IGF-II and FGF-2 was used to define growth factor expression at the cartilage wound sites. RESULTS: Almost no effect of cartilage wounding was observed one day after surgery. A decrease of proteoglycan content, with a maximal loss at day 7, and a subsequent restoration was observed at the wound edges. Growth factor expression increased simultaneously. Maximal immunostaining for IGF1, IGFII, FGF2 and TGF-beta3 was observed at day 7, followed by a gradual decrease. Increased expression of TGFbeta1 lasted from day 3 until day 14. CONCLUSION: We have demonstrated the ability of chondrocytes to increase growth factor expression and to restore the rapid decrease in proteoglycan content in the initial phase following acute wounding. A temporal increase in intracellular growth factor expression suggests an autocrine and/or paracrine metabolic stimulation, which can be regarded a sign of chondrocytes repair capacity.</description>
    </item> <item>
      <title>Fixation-dependent immunolocalization shift and immunoreactivity of intracellular growth factors in cartilage (Article)</title>
      <link>http://repub.eur.nl/res/pub/14736/</link>
      <pubDate>2000-01-01T00:00:00Z</pubDate>
      <description>The effects of fixation on immunolocalization and immunoreactivity in cartilage tissues were studied using monoclonal antibodies against peptides that can effectively stimulate chondrocytes in vitro and have been shown to play a role in musculoskeletal tissue regeneration: transforming growth factor β1, transforming growth factor β3, insulin-like growth factor I, insulin-like growth factor II and fibroblast growth factor 2. Paraffin sections fixed in buffered formalin, buffered paraformaldehyde, Carnoy and methacarn, as well as cryosections, were tested. A strong immunoreaction was observed in tissue fixed in formaldehyde-based fixatives, with a resemblance to that in cryopreserved tissues. Immunoreactivity was reduced in alcohol-fixed tissues. Furthermore, a striking intracellular immunolocalization shift from cytoplasm to nucleus was observed using alcohol-based fixatives as compared to cryopreserved or formaldehyde-based fixatives. We concluded that, for the detection and localization of growth factors in cartilage tissues, fixation in buffered formalin or paraformaldehyde is optimal.</description>
    </item>
  </channel>
</rss>